Name: PLX-4720
Price: 220.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    PLX-4720, a 7-azaindole derivative discovered by a structure-guided discovery approach, is a potent inhibitor of B-RafV600E, the most frequent oncogenic protein kinase mutation, with the value of 50% inhibition concentration IC50 of 13 nM. PLX-4720 exhibits selective inhibition against B-RafV600E rather than wild type B-Raf (IC50 = 160 nM) as well as a wide range of other kinases, such as FRK, CSK, SRC, FAK, FGFR, and Aurora A (IC50 > 1000 nM for all). PLX-4720 potently inhibits ERK phosphorylation in tumor cell lines harboring B-RafV600E, induces cell cycle arrest and apoptosis in B-RafV600E-positive melanoma cells and causes tumor growth delays in B-RafV600E-dependent tumor xenograft models through oral administration.
- Properties
  - Alternative Name
    
    PLX4720, PLX-4720, PLX 4720; N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide
    
    CAS Number
    
    918505-84-7
    
    Molecular Formula
    
    C17H14ClF2N3O3S
    
    Molecular Weight
    
    413.83
    
    Appearance
    
    A solid
    
    Purity
    
    98.70%
    
    Solubility
    
    ≥20.69 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
    
    Storage
    
    Store at 4°C
    
    * For Research Use Only
- Reference
  - 1. Sieber J, Wieder N, et al. "GDC-0879, a BRAF(V600E) Inhibitor, Protects Kidney Podocytes from Death." Cell Chem Biol. 2017 Dec 6. PMID:29249695